Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Application of immunosignatures to the assessment of Alzheimer's disease.

Restrepo L, Stafford P, Magee DM, Johnston SA.

Ann Neurol. 2011 Aug;70(2):286-95. doi: 10.1002/ana.22405.

PMID:
21823156
2.

Feasibility of an early Alzheimer's disease immunosignature diagnostic test.

Restrepo L, Stafford P, Johnston SA.

J Neuroimmunol. 2013 Jan 15;254(1-2):154-60. doi: 10.1016/j.jneuroim.2012.09.014. Epub 2012 Oct 18.

PMID:
23084373
3.

[Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].

Robert PH, Schuck S, Dubois B, Lépine JP, Gallarda T, Olié JP, Goni S, Troy S.

Encephale. 2003 May-Jun;29(3 Pt 1):266-72. French.

PMID:
12876552
4.

Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patients.

Le Bastard N, Leurs J, Blomme W, De Deyn PP, Engelborghs S.

J Alzheimers Dis. 2010;21(1):291-301. doi: 10.3233/JAD-2010-091501.

PMID:
20421698
5.

Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers.

Meli G, Visintin M, Cannistraci I, Cattaneo A.

J Mol Biol. 2009 Apr 3;387(3):584-606. doi: 10.1016/j.jmb.2009.01.061. Epub 2009 Feb 4.

PMID:
19361429
6.

Concomitant detection of beta-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice.

Härtig W, Goldhammer S, Bauer U, Wegner F, Wirths O, Bayer TA, Grosche J.

J Chem Neuroanat. 2010 Sep;40(1):82-92. doi: 10.1016/j.jchemneu.2010.03.006. Epub 2010 Mar 25.

PMID:
20347032
7.

Antibody-based therapy in Alzheimer's disease.

Pul R, Dodel R, Stangel M.

Expert Opin Biol Ther. 2011 Mar;11(3):343-57. doi: 10.1517/14712598.2011.552884. Epub 2011 Jan 25. Review.

PMID:
21261567
8.

Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.

Oddo S, Caccamo A, Cheng D, Jouleh B, Torp R, LaFerla FM.

J Neurochem. 2007 Aug;102(4):1053-63. Epub 2007 Apr 30.

9.

Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease.

Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, Rajadas J, Zhang H, Tomooka B, Robinson WH, Clark CM, Fagan AM, Galasko DR, Holtzman DM, Jutel M, Kaye JA, Lemere CA, Leszek J, Li G, Peskind ER, Quinn JF, Yesavage JA, Ghiso JA, Wyss-Coray T.

Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12145-50. doi: 10.1073/pnas.0904866106. Epub 2009 Jul 6.

10.

Amyloid beta-HSP60 peptide conjugate vaccine treats a mouse model of Alzheimer's disease.

Nemirovsky A, Fisher Y, Baron R, Cohen IR, Monsonego A.

Vaccine. 2011 May 23;29(23):4043-50. doi: 10.1016/j.vaccine.2011.03.033. Epub 2011 Apr 5.

PMID:
21473952
11.

Transgenic mouse models of Alzheimer's disease: phenotype and application.

Higgins GA, Jacobsen H.

Behav Pharmacol. 2003 Sep;14(5-6):419-38. Review.

PMID:
14501255
12.

Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry.

Oe T, Ackermann BL, Inoue K, Berna MJ, Garner CO, Gelfanova V, Dean RA, Siemers ER, Holtzman DM, Farlow MR, Blair IA.

Rapid Commun Mass Spectrom. 2006;20(24):3723-35.

PMID:
17117458
13.

I32E and V36K double mutation in beta2-sheet abrogates amyloid beta peptide toxicity.

Subramanian S, Mishra PK, Bandopadhyay D.

Indian J Exp Biol. 2010 Nov;48(11):1098-102.

PMID:
21117449
14.

Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease.

Holtzman DM, Bales KR, Paul SM, DeMattos RB.

Adv Drug Deliv Rev. 2002 Dec 7;54(12):1603-13. Review.

PMID:
12453677
15.

Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice.

Kane MD, Lipinski WJ, Callahan MJ, Bian F, Durham RA, Schwarz RD, Roher AE, Walker LC.

J Neurosci. 2000 May 15;20(10):3606-11.

16.

Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models.

Götz J, Schild A, Hoerndli F, Pennanen L.

Int J Dev Neurosci. 2004 Nov;22(7):453-65. Review.

PMID:
15465275
17.

[Treatment strategy of Alzheimer's disease: pause in clinical trials of Abeta vaccine and next steps].

Kuzuhara S.

Brain Nerve. 2010 Jul;62(7):659-66. Review. Japanese.

PMID:
20675870
18.

CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease.

Mollenhauer B, Esselmann H, Trenkwalder C, Schulz-Schaeffer W, Kretzschmar H, Otto M, Wiltfang J, Bibl M.

J Alzheimers Dis. 2011;24(2):383-91. doi: 10.3233/JAD-2011-101551.

PMID:
21297274
19.

Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide.

Moretto N, Bolchi A, Rivetti C, Imbimbo BP, Villetti G, Pietrini V, Polonelli L, Del Signore S, Smith KM, Ferrante RJ, Ottonello S.

J Biol Chem. 2007 Apr 13;282(15):11436-45. Epub 2007 Jan 31.

20.

Modulation of Alzheimer's pathology by cerebro-ventricular grafting of hybridoma cells expressing antibodies against Abeta in vivo.

Gaugler MN, Tracy J, Kuhnle K, Crameri A, Nitsch RM, Mohajeri MH.

FEBS Lett. 2005 Jan 31;579(3):753-6.

Supplemental Content

Support Center